编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel may be superior to the already highly effective standard medicine Gleevec in treating newly diagnosed patients with chronic ...

Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia This is an ASCO Meeting Abstract from the 2009 ASCO Annual ...

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...

Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects No significant financial ...

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers ...

STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...

Sprycel, Tasigna, and Gleevec battle for supremacy in CML treatment. FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel®, and ...